Form 4: Capricor Director's Option Exercise Raises Date Questions

Capricor Therapeutics director George W. Dunbar Jr. reported an option exercise for 3,000 shares, but the transaction date appears after the option's stated expiration.

Summary

• George W. Dunbar Jr., a director of Capricor Therapeutics, Inc. (CAPR), reported exercising stock options on December 19, 2025.
• He acquired 3,000 shares of common stock at an exercise price of $1.39 per share.
• Following this transaction, Dunbar directly owns 14,306 shares of Capricor Therapeutics common stock.
• The exercised option was originally granted on June 2, 2016, for 30,000 shares at an exercise price of $3.12 per share.
• The option was adjusted due to a 1-for-10 reverse stock split on June 4, 2019, and a reprice to $1.39 per share on February 12, 2020, resulting in the current 3,000 shares at $1.39.
• The option was fully vested and exercisable as of December 31, 2016, and had a stated expiration date of March 3, 2025.
• A significant discrepancy exists as the reported transaction date of December 19, 2025, is after the stated option expiration date of March 3, 2025, which typically would prevent such an exercise.

Sentiment

Score: 3

Explanation: The filing contains a significant inconsistency where the option exercise date (December 19, 2025) is after the stated option expiration date (March 3, 2025). This raises serious concerns about the accuracy and validity of the reported transaction, overshadowing any potential positive signal from a director's option exercise.

Positives

• A director exercising options can, in general, signal confidence in the company's future prospects, as they are choosing to convert their options into shares, assuming the transaction is valid.

Negatives

• The reported transaction date (December 19, 2025) is after the stated expiration date of the option (March 3, 2025), which is an unusual and potentially problematic inconsistency that could indicate a clerical error or an undisclosed special circumstance.

Risks

• The discrepancy between the transaction date (December 19, 2025) and the option expiration date (March 3, 2025) could raise questions about the validity of the exercise or the accuracy of the filing, potentially leading to further scrutiny or requiring clarification from the company.
• Inaccurate or inconsistent regulatory filings can erode investor confidence and potentially lead to regulatory inquiries.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider transactions like option exercises are common across all industries. For Capricor Therapeutics, a biotechnology company, such transactions are typically viewed in the context of the company's clinical development progress and market valuation. However, the inconsistency in dates within this filing introduces an unusual element that deviates from standard industry reporting practices.

Stakeholder Impact

• Shareholders: The critical date inconsistency could lead to uncertainty and potentially erode confidence in the accuracy of the company's regulatory filings.
• Regulatory Authorities: The discrepancy may prompt inquiries from the SEC regarding the accuracy and compliance of the filing.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific transaction, but a loss of investor confidence could indirectly affect the company's standing.

Next Steps

• The company is expected to issue a clarification or amendment to address the discrepancy between the transaction date and the option expiration date.

Key Dates

Recommendation

While a director's option exercise can be a positive signal, this filing contains a critical inconsistency: the transaction date (December 19, 2025) is after the stated option expiration date (March 3, 2025). This raises serious questions about the accuracy of the filing and the validity of the transaction. Investors should 'hold' existing positions and await immediate clarification from Capricor Therapeutics regarding this discrepancy, as it introduces uncertainty and potential regulatory scrutiny.

Keywords

Capricor Therapeutics, CAPR, Form 4, Insider Transaction, Stock Option Exercise, Director, Equity Acquisition, Regulatory Filing Discrepancy